Skip to content

Application of nano-platelet in the repair of skin degloved injury

Application of nano-platelet in the repair of skin degloved injury

Status
Active, not recruiting
Phases
Early Phase 1
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2400086258
Enrollment
Unknown
Registered
2024-06-27
Start date
2024-07-01
Completion date
Unknown
Last updated
2024-07-08

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

skin degloved injury

Interventions

Control group:1) Debridement is performed on the subjects to remove the clearly necrotic tissue and leave the skin tissue that could survive in situ for replantation. 2) Dress the wound with sterile g

Sponsors

department of Orthopedic surgery, Sir Run Run Shaw Hospital, Zhejiang University School of Medicine
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 65 Years

Inclusion criteria

Inclusion criteria: 1) Extremity skin avulsion injuries or stealth detachment injuries caused by various causes 2) The time from injury to initial debridement is less than or equal to 72 hours 3) With or without bone fracture 4) The surface area of the skin avulsion wound is greater than 5*5cm 5) 18-65 years old

Exclusion criteria

Exclusion criteria: 1) Active cellulitis 2) Osteomyelitis 3) History of open injury or scarring of the previous injured area 4) Combined thoracoabdominal and cerebral injuries, unstable vital signs, unable to tolerate multiple limb-salvage surgeries 5) Revascularization was performed in the last 6 weeks(Ipsilateral lower extremity) 6) Taken any experimental drug or applied topically to the wound 4 weeks prior to the study 7) Presence of significant medical conditions that would impair wound healing, such as aplastic anemia, liver disease, scleroderma, malignancy, or immunosuppressive therapy 8) Patients who are participating in other clinical trials 9) Specimen collection was not satisfactory 10) Vulnerable groups, including people with mental illness, cognitive impairment, critically ill patients, minors, pregnant women, etc. 11) Other reasons that are considered unsuitable by the investigators to participate in this study

Design outcomes

Primary

MeasureTime frame
Wound area;Immunofluorescence;

Secondary

MeasureTime frame
RNA sequence;

Countries

China

Contacts

Public ContactXianfeng Lin

Sir Run Run Shaw Hospital, School of Medicine, Zhejiang University

Xianfeng_lin@zju.edu.cn+86 152 6884 3719

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026